New guidance offers glucose management strategies that limit direct contact, minimize clinicians’ risk
The COVID-19 pandemic presents new challenges for clinicians caring for infected patients with diabetes, according to new guidance published in the Endocrine Society’s Journal of Clinical Endocrinology & Metabolism.
Hospitalized patients with COVID-19 and diabetes need to receive glucose–lowering therapy in addition to other complex medical management as a way of minimizing risk for complications and death. However, appropriate glycemic management—including bedside glucose monitoring and insulin administration—requires intensive patient interactions and puts clinicians at risk.
“This manuscript provides guidance for healthcare providers caring for patients hospitalized for COVID-19 who also have a prior history of diabetes or who have high blood sugar levels at the time of hospitalization,” said lead author Mary T. Korytkowski, M.D., of the University of Pittsburgh School of Medicine in Pittsburgh, Pa. “These healthcare providers are at risk for contracting COVID-19, and while glycemic management in the hospital improves patient outcomes, it also intensifies the amount of time with direct patient contact.”
Clinicians may limit their risk of exposure by minimizing the use of IV insulin infusions and using remote glucose monitoring devices and non-insulin therapies when possible. Diabetes self-management by selected patients who are knowledgeable and capable of this in the hospital also can be considered as a way of limiting direct patient interactions. Clinicians should be aware that some medications used in treating COVID-19 patients, including glucocorticoids and hydroxychloroquine, can affect blood glucose levels.
Other authors include Kellie Antinori-Lent of the University of Pittsburgh Medical Center Shadyside Hospital in Pittsburgh, Pa.; Andjela Drincic of the University of Nebraska Medical Center in Omaha, Neb.; Irl B. Hirsch of the University of Washington in Seattle, Wash.; Marie E. McDonnell of Brigham and Women’s Hospital and Harvard Medical School in Boston, Mass.; Robert Rushakoff of the University of California in San Francisco, Calif.; and Ranganath Muniyappa of the National Institutes of Health in Bethesda, Md.
The study did not receive external funding.